Successful exit for PVP: Cytiva buys our portfolio Company CEVEC
CEVEC is now part of Cytiva
Cologne, Germany, October 6th, 2022
About CEVEC
CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics.
With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free inducible producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents nor cGMP plasmids. CEVEC's CAP® Ad Technology is the ideal production platform for RCA-free Adenoviral vectors. Based on human suspension cells, it allows for a robust manufacturing process, easy scale-up from research grade to industrial volumes and thus opens the way for various applications, from gene therapy to vaccine production.
For more information, please visit the Company’s website.
Follow CEVEC on LinkedIn and Twitter.
About Cytiva
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in more than 40 countries dedicated to customers' speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
For more information, please visit the Company’s website.
Follow Cytiva on LinkedIn and Twitter.
Contact
Dodi Axelson
Head of Communications, Cytiva
Dodi.axelson@cytiva.com